Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The price of Novo Nordisk ADR (NYSE: NVO) closed at $54.78 in the last session, up 1.92% from day before closing price of $53.75. In other words, the price has increased by $1.92 from its previous closing price. On the day, 25.68 million shares were traded. NVO stock price reached its highest trading level at $55.48 during the session, while it also had its lowest trading level at $54.02.
Ratios:
We take a closer look at NVO’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 61.90 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 19.43. For the most recent quarter (mrq), Quick Ratio is recorded 0.56 and its Current Ratio is at 0.78. In the meantime, Its Debt-to-Equity ratio is 0.59 whereas as Long-Term Debt/Eq ratio is at 0.52.
HSBC Securities Downgraded its Buy to Hold on July 31, 2025, while the target price for the stock was maintained at $57.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 30 ’25 when Novo Nordisk A/S bought 921,897 shares for $2.14 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVO now has a Market Capitalization of 230349897728 and an Enterprise Value of 319168380928. As of this moment, Novo’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.09, and their Forward P/E ratio for the next fiscal year is 12.95. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.12. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.06 while its Price-to-Book (P/B) ratio in mrq is 9.20. Its current Enterprise Value per Revenue stands at 1.023 whereas that against EBITDA is 2.004.
Stock Price History:
The Beta on a monthly basis for NVO is 0.65, which has changed by -0.59410197 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, NVO has reached a high of $139.74, while it has fallen to a 52-week low of $45.05. The 50-Day Moving Average of the stock is -14.75%, while the 200-Day Moving Average is calculated to be -30.45%.
Shares Statistics:
According to the various share statistics, NVO traded on average about 14.75M shares per day over the past 3-months and 23670430 shares per day over the past 10 days. A total of 3.37B shares are outstanding, with a floating share count of 3.37B. Insiders hold about 0.00% of the company’s shares, while institutions hold 9.36% stake in the company. Shares short for NVO as of 1753920000 were 20756474 with a Short Ratio of 1.41, compared to 1751241600 on 25701254. Therefore, it implies a Short% of Shares Outstanding of 20756474 and a Short% of Float of 0.62.
Dividends & Splits
The forward annual dividend rate for NVO is 1.73, which was 11.65 in the trailing 12 months. Against a Trailing Annual Dividend Yield of 0.21674418The stock’s 5-year Average Dividend Yield is 1.49. The current Payout Ratio is 35.93% for NVO, which recently paid a dividend on 2025-03-31 with an ex-dividend date of 2025-03-31. Stock splits for the company last occurred on 2023-09-20 when the company split stock in a 2:1 ratio.
Earnings Estimates
Investors are keenly observing as 4.0 analysts analyze and rate the current performance of Novo Nordisk ADR (NVO) in the stock market.The consensus estimate for the next quarter is $6.03, with high estimates of $6.49 and low estimates of $5.69.
Analysts are recommending an EPS of between $25.9 and $23.81 for the fiscal current year, implying an average EPS of $24.84. EPS for the following year is $25.52, with 3.0 analysts recommending between $25.89 and $25.16.
Revenue Estimates
According to 9 analysts, the current quarter’s revenue is expected to be $77.65B. It ranges from a high estimate of $85.77B to a low estimate of $74.03B. As of the current estimate, Novo Nordisk ADR’s year-ago sales were $71.31BFor the next quarter, 9 analysts are estimating revenue of $84.05B. There is a high estimate of $99.99B for the next quarter, whereas the lowest estimate is $79.59B.
A total of 22 analysts have provided revenue estimates for NVO’s current fiscal year. The highest revenue estimate was $353.05B, while the lowest revenue estimate was $309.51B, resulting in an average revenue estimate of $320.25B. In the same quarter a year ago, actual revenue was $290.4BBased on 22 analysts’ estimates, the company’s revenue will be $349.4B in the next fiscal year. The high estimate is $405.13B and the low estimate is $317.52B.
